论文部分内容阅读
目的 在实验性自身免疫性重症肌无力 (EAMG)动物模型采用双类似物进行鼻黏膜免疫耐受 ,观察其临床及免疫功能变化 ,评价疗效并探讨其作用机制。方法 建立Lewis大鼠EAMG动物模型 ,选取经预实验证实有效的最低剂量为治疗量 ,检测致敏同时 (A组 )和缓解期第 1天 (B组 )给予以类似物鼻黏膜免疫耐受治疗后 ,大鼠体重、临床症状、致敏第 35天血清抗AChR抗体IgG含量及其淋巴细胞在不同刺激原作用下的增殖情况。结果 ①治疗后EAMG大鼠体重增加 ,临床症状缓解。②治疗后血清抗AChR抗体IgG含量 (吸光度 ,A值 ) :A组 (0 .98± 0 .2 4 )和B组 (0 .95± 0 .2 6 )均少于各自对照组 (分别为 1.18± 0 .10和1.19± 0 .12 ) ,但A、B组间差异无显著意义。③针对AChR等特异性抗原的淋巴细胞增殖指数 :A组 (1.71± 0 .78)和B组 (1.97± 0 .5 6 )与对照组 (3.2 4± 1.31和 3.19± 1.5 0 )相比均减低 ,增殖反应明显受抑制。结论 双类似物鼻黏膜耐受能明显缓解EAMG的肌无力症状 ,并伴有特异性T、B细胞免疫功能抑制。
OBJECTIVE: To investigate the clinical and immunological changes of nasal mucosa by double analogues in experimental autoimmune myasthenia gravis (EAMG) animal model and to evaluate the curative effect and explore its mechanism. Methods The animal model of EAMG in Lewis rats was established. The lowest dose pre-tested and validated as the therapeutic dose was selected. Nasal mucosal immunological tolerance was given simultaneously (group A) and on the first day of remission (group B) After the body weight, clinical symptoms, serum anti-AChR antibody IgG levels on the 35th day after sensitization and the proliferation of lymphocytes under different stimuli, Results ① The body weight of EAMG rats increased and the clinical symptoms were relieved after treatment. ② After treatment, the serum anti-AChR antibody IgG content (absorbance, A value): A group (0.98 ± 0.24) and B group (0.95 ± 0.26) were less than the respective control group 1.18 ± 0.10 and 1.19 ± 0.12), but there was no significant difference between A and B groups. (3) The lymphocyte proliferation index of specific antigen such as AChR: A group (1.71 ± 0.78) and B group (1.97 ± 0.56) compared with the control group (3.2 4 ± 1.31 and 3.19 ± 1.5 0) Reduce, proliferative response was significantly inhibited. Conclusions The nasal mucosal tolerance of double analogues can relieve the symptoms of muscle weakness of EAMG obviously, accompanied with the suppression of specific T and B cell immune function.